Auctus Biologics, Inc., a Lafayette, NY-based biotechnology company, closed $1.5m in seed funding.
The backers were not disclosed.
Founded in 2018 and led by Kelsey Moody, CEO, and Aaron Wolfe, COO, Auctus Biologics will develop RPtag, a hyper-stable antibody mimetic scaffold, to take on conventional clinical antibody therapy as an orally bioavailable formulation.
New immunosenescence and gastrointestinal targets will also be pursued.
Auctus is a new portfolio company of Ichor Therapeutics, a vertically integrated research organization focused on diseases and pathways of aging.